 Fate Therapeutics Inc NASDAQ: FATE has announced interim data from Phase 1 data from the Companys off-the-shelf, iPSC-derived natural killer NK cell programs in relapsed refractory acute myeloid leukemia AML. Data come from two Phase 1 dose-escalation studies that are evaluating FT516 and FT538 as monotherapy. 